By Amir Shroufi, MSF South Africa Outsiders seldom get the attention they deserve. When it comes to conservation, for example, a few popular species attract most of the available funding – the rhino overshadows riverine rabbit. In the arts, jazz and blues struggle to attract the attention given freely to catchy pop, and it’s rare to … Read more
Today, as preliminary AMBITION trial results demonstrated a breakthrough in treatment of HIV-related cryptococcal meningitis, simplifying and shortening treatment by using a single dose of liposomal amphotericin B (L-AmB) in combination with existing oral therapy, Médecins Sans Frontières/Doctors Without Borders (MSF) called on the US pharmaceutical corporation Gilead Sciences, the world’s key supplier of quality-assured … Read more
Inaction by US pharmaceutical corporation Gilead to follow through on its so-called ‘access initiative’ leaves people unable to access a vital drug to treat a deadly infection. Delhi/Geneva – Pharmaceutical corporation Gilead Sciences has failed to deliver on promises to make an important drug available to people suffering from a life-threatening HIV-related infection, the medical humanitarian … Read more